A Short-Term Increase Of The Postoperative Naturally Circulating Dendritic Cells Subsets In Flurbiprofen-Treated Patients With Esophageal Carcinoma Undergoing Thoracic Surgery

The present study evaluated whether flurbiprofen increased the naturally circulating dendritic cells (DCs) subsets in patients with esophageal squamous cell carcinoma (ESCC) undergoing esophageal resection. Compared to healthy donors (n=20), the significantly depressed percentages of plasmacytoid DCs (pDCs), CD1c(+) myeloid DCs (mDCs), and CD141(+) mDCs among ESCC patients (n=60) were confirmed. Flurbiprofen was administered before skin incision and at the end of operation in group F (n=30), as well as placebo in group C (n=30). The postoperative suppressed percentages of pDCs, CD1c(+) mDCs, and CD141(+) mDCs increased significantly following the perioperative treatment with flurbiprofen. Flurbiprofen also significantly stimulated the postoperative IFN-gamma and IL-17 production, but inhibited the immunosuppressive IL-10 and TGF-beta levels. Furthermore, flurbiprofen exerted a similar analgesic effect and brought a significantly less sufentanil consumption compared to group C. Taken together, flurbiprofen provided a short-term increase of postoperative naturally circulating DCs in ESCC patients.